Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | ELANE | P08246 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.36 |
| ▸ | BRD4 | O60885 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.34 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2110142 | 0.80 | ADORA2A (0.58) | ADORA2AL3MBTL1ALDH1A1KDM4ENPSR1 | |
| SCHEMBL2109041 | 0.74 | GABRA1 (0.39) | ADORA2AL3MBTL1ALDH1A1KDM4ENPSR1 | |
| SCHEMBL5667457 | 0.74 | ADORA2A (1.00) | ADORA2AALDH1A1KDM4ENPSR1RXFP1 | |
| SCHEMBL2109986 | 0.71 | MAPT (0.39) | L3MBTL1ALDH1A1NPSR1ELANESMN1; SMN2 | |
| SCHEMBL31318409 | 0.65 | L3MBTL1 (0.48) | ADORA2AL3MBTL1ALDH1A1KDM4ENPSR1 | |
| SCHEMBL19545057 | 0.65 | LRRK2 (0.64) | ADORA2ALRRK2BRD4 | |
| SCHEMBL8318430 | 0.65 | L3MBTL1 (0.46) | L3MBTL1ALDH1A1ELANEPOLBTDP1 | |
| SCHEMBL19520760 | 0.63 | LRRK2 (0.60) | ADORA2ANPSR1LRRK2BRD4 | |
| SCHEMBL2434846 | 0.61 | ALDH1A1 (0.56) | ADORA2AALDH1A1KDM4ENPSR1LRRK2 | |
| SCHEMBL23111604 | 0.61 | LRRK2 (0.60) | ADORA2AALDH1A1KDM4ENPSR1LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165327-A1 | SPIROPIPERIDINES FOR USE AS TRYPTASE INHIBITORS | COSTANZO MICHAEL J (US) | 2012-06-28 | — | — | US | claimed |
| US-8158792-B2 | Spiropiperidines for use as tryptase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-04-17 | — | — | US | claimed |
| EP-2224803-A1 | SPIROPIPERIDINES FOR USE AS TRYPTASE INHIBITORS | Janssen Pharmaceutica N.V. (BE) | 2010-09-08 | — | — | EP | claimed |
| US-20090163527-A1 | Spiropiperidines for use as tryptase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2009-06-25 | — | — | US | claimed |
| WO-2009067202-A1 | SPIROPIPERIDINES FOR USE AS TRYPTASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-05-28 | — | — | WO | claimed |
| US-8536189-B2 | Spiropiperidines for use as tryptase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2013-09-17 | — | — | US | disclosed |
| US-20120165327-A1 | SPIROPIPERIDINES FOR USE AS TRYPTASE INHIBITORS | COSTANZO MICHAEL J (US) | 2012-06-28 | — | — | US | disclosed |
| US-8158792-B2 | Spiropiperidines for use as tryptase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-04-17 | — | — | US | disclosed |
| EP-2224803-A1 | SPIROPIPERIDINES FOR USE AS TRYPTASE INHIBITORS | Janssen Pharmaceutica N.V. (BE) | 2010-09-08 | — | — | EP | disclosed |
| US-20090163527-A1 | Spiropiperidines for use as tryptase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2009-06-25 | — | — | US | disclosed |
| WO-2009067202-A1 | SPIROPIPERIDINES FOR USE AS TRYPTASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165327-A1 | SPIROPIPERIDINES FOR USE AS TRYPTASE INHIBITORS | TPSAB1, TPSB2, TPSD1 | ADORA2A 1002/4885L3MBTL1 4857/4885ALDH1A1 450/4885 |
| US-20090163527-A1 | Spiropiperidines for use as tryptase inhibitors | TPSAB1, TPSB2, TPSD1 | ADORA2A 1002/4885L3MBTL1 4857/4885ALDH1A1 450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.